Uremic Pruritus
Conditions
Keywords
CR845, difelikefalin, Pruritus, Chronic Itch, Itch, Itching, hemodialysis, Uremic Pruritus, Dialysis, CKD, CKD-associated pruritus, CKD-aP, ESRD (end stage renal disease), Chronic Kidney Disease, Kidney failure, chronic, Kidney dysfunction, Generalized pruritus
Brief summary
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Detailed description
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks. This study will consist of a Screening Visit, a 52 week Treatment Period, and a Follow-up Visit. Informed consent will be obtained prior to performing any study-specific procedures. All patients will have a Screening Visit, which can be performed anytime within 14 days prior to the first dose of study drug, to confirm eligibility. Clinical laboratory tests, electrocardiograms (ECGs), vital signs, adverse events, and concomitant medications will be monitored throughout the study. Blood samples for inflammatory biomarkers will be collected from all patients prior to dialysis on Day 1 and periodically until the End of Treatment or Early Termination Visit. Blood samples will also be collected periodically for clinical laboratory tests.
Interventions
DRUGCR845
IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Sponsors
Cara Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be eligible for inclusion into the study, a patient must meet the following criteria: 1. Willing and able to provide written informed consent prior to participating in this study; 2. Able to communicate clearly with the Investigator and staff, able to understand the study procedures, and able and willing to comply with the study schedules and all study requirements; 3. Males or females 18 years of age or older; 4. Currently on hemodialysis for end-stage renal disease and has been categorized as experiencing moderate to severe uremic pruritus; 5. If female: 1. Is not of childbearing potential (surgically sterile or postmenopausal, as defined in Section 6.5.1.6); or 2. Has a negative serum pregnancy test at screening and agrees to use acceptable contraceptive measures (as defined in Section 6.5.1.6) from the time of informed consent until the safety Follow-up Visit or 7 days after the last dose of study drug, whichever is later. 6. If male, agrees not to donate sperm after the first dose of study drug until 7 days after the last dose, and agrees to use a condom with spermicide or abstain from heterosexual intercourse during the study until 7 days after study drug administration. (Note: No restrictions are required for a vasectomized male provided his vasectomy was performed ≥4 months prior to dosing); 7. Has a dry body weight of ≥40.0 kg at screening (prescription target dry body weight); 8. Has adequacy of dialysis, defined as meeting 1 of the following criteria during the 3 months prior to screening: 1. ≥2 single pool Kt/V measurements ≥1.2; or 2. ≥2 urea reduction ratio measurements ≥65%; or 3. 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65%
Exclusion criteria
A patient will be excluded from the study if any of the following criteria are met: 1. Received an investigational drugwithin 30 days prior to the first dose of study drug, or is planning to participate in another interventional clinical study while enrolled in this study. 2. Has a concomitant disease or any medical condition that, in the opinion of the Investigator, could pose undue risk to the patient, impede completion of the study procedures, or would compromise the validity of the study measurements, including, but not limited to: 1. Known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, -diagnosed alcohol, narcotic or other drug abuse, or substance dependence within 12 months prior to screening; 2. New York Heart Association Class IV congestive heart failure (Appendix 1, Section 14.0); 3. Severe mental illness or cognitive impairment (eg, dementia); 4. Any other relevant acute or chronic medical or neuropsychiatric condition;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With AEs | Up to 52 weeks | Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments |
Countries
Puerto Rico, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CR845 0.5mcg/kg CR845 0.5mcg/kg IV medication administered three times/week after dialysis
CR845: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week) | 288 |
| Total | 288 |
Baseline characteristics
| Characteristic | CR845 0.5mcg/kg |
|---|---|
| Age, Continuous | 57.4 years STANDARD_DEVIATION 12.61 |
| Race (NIH/OMB) American Indian or Alaska Native | 12 Participants |
| Race (NIH/OMB) Asian | 9 Participants |
| Race (NIH/OMB) Black or African American | 148 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 114 Participants |
| Sex: Female, Male Female | 115 Participants |
| Sex: Female, Male Male | 173 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 17 / 288 |
| other Total, other adverse events | 139 / 288 |
| serious Total, serious adverse events | 148 / 288 |
Outcome results
Primary
Number of Participants With AEs
Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments
Time frame: Up to 52 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CR845 0.5mcg/kg | Number of Participants With AEs | 240 Participants |